Table 6.

OS and PFS of initial lenvatinib treatment with subsequent selective TACE in proof-of-concept study

	Lenvatinib (followed by selectiveTACE)	TACE	HR p value
Median OS, months	37.9 (23.1-NR)	21.3 (15.7–28.4)	0.48 (0.16–0.79) <0.01
Median PFS, months	16.0 (10.9–16.6)	3.0 (2.1–4.3)	0.19 (0.10–0.35) <0.001

Values in parentheses are 95% CI. Cited and modified from Kudo et al. [34]. TACE, transcatheter arterial chemoembolization; OS, overall survival; PFS, progression-free survival; NR, not reached.